ABT Abbott Laboratories

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Abbott Labs (ABT - Research Report) on November 3 and set a price target of $126.00. The company's shares closed yesterday at $98.07.Singh Chadha covers the Healthcare sector, focusing on stocks such as Abbott Labs, Boston Scientific, and Medtronic. According to TipRanks, Singh Chadha has an average return of -12.2% and a 23.33% success rate on recommended stocks. In addition to RBC Capital, Abbott Labs also received a Buy from Barclays's Matt Miksic in a report issued on October 21. However, on October 26, Mizuho Securities initiated coverage with a Hold rating on Abbott Labs (NYSE: ABT).
https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-abbott-labs-abt?utm_source=advfn.com&utm_medium=referral